SCM
SABSW icon

Shaolin Capital Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Shaolin Capital Management’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-465,717
Closed -$49K – 607
2023
Q2 		$49K Buy
+465,717
New +$48.7K ﹤0.01% 381

Other funds holding SABSW

HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Shaolin Capital Management's SABSW Position: Q3 2024 in Review

Shaolin Capital Management sold out of SAB Biotherapeutics Warrant (SABSW) in Q3 2024, closing a stake of 249,143 shares — an estimated $11.8K sold.

Shaolin Capital Management first reported a position in SABSW in Q1 2021 and held it in 13 quarters. The position peaked at $1.51M in Q4 2021. 9 funds tracked by Wall St. Rank hold SABSW as of Q3 2024.

  • Shaolin Capital Management reported no remaining SAB Biotherapeutics Warrant position as of Q3 2024 after selling out during the quarter.
  • Shaolin Capital Management sold 249,143 SAB Biotherapeutics Warrant shares in Q3 2024, an estimated $11.8K.
  • Shaolin Capital Management first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and held it in 13 quarters.
  • Shaolin Capital Management's SAB Biotherapeutics Warrant position peaked at $1.51M in Q4 2021.
  • 9 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q3 2024.

Based on Shaolin Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.